Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 537306, 7 pages
http://dx.doi.org/10.1155/2014/537306
Review Article

Pharmacological Treatments in Gambling Disorder: A Qualitative Review

1Department of Neuroscience and Imaging, University “G. d’Annunzio”, Chieti, Italy
2Department of Psychiatry, Drug Addiction Unit, Catholic University Medical School, Rome, Italy

Received 26 February 2014; Accepted 23 April 2014; Published 18 May 2014

Academic Editor: Ornella Corazza

Copyright © 2014 Matteo Lupi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. APA, Diagnostic and Statistical Manual, American Psychiatric Association, Arlington, Va, USA, 5th edition, 2013.
  2. B. Dell'Osso, A. C. Altamura, A. Allen, D. Marazziti, and E. Hollander, “Epidemiologic and clinical updates on impulse control disorders: a critical review,” European Archives of Psychiatry and Clinical Neuroscience, vol. 256, no. 8, pp. 464–475, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Villella, G. Martinotti, M. Di Nicola et al., “Behavioural addictions in adolescents and young adults: results from a prevalence study,” Journal of Gambling Studies, vol. 27, no. 2, pp. 203–214, 2011. View at Google Scholar · View at Scopus
  4. J. E. Grant and S. W. Kim, “Demographic and clinical features of 131 adult pathological gamblers,” Journal of Clinical Psychiatry, vol. 62, no. 12, pp. 957–962, 2001. View at Google Scholar · View at Scopus
  5. G. Martinotti, S. Andreoli, E. Giametta, V. Poli, P. Bria, and L. Janiri, “The dimensional assessment of personality in pathologic and social gamblers: the role of novelty seeking and self-transcendence,” Comprehensive Psychiatry, vol. 47, no. 5, pp. 350–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. E. Grant and M. N. Potenza, Ll Gioco D’azzardo Patologico—Una guida Clinica al Trattamento, Springer, 2010.
  7. M. Pettorruso, G. Martinotti, A. Fasano et al., “Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study,” Psychiatry Research, vol. 215, no. 2, pp. 448–452, 2014. View at Publisher · View at Google Scholar
  8. J. E. Grant, B. L. Odlaug, and L. R. Schreiber, “Pharmacological treatments in pathological gambling,” British Journal of Clinical Pharmacology, vol. 77, no. 2, pp. 375–381, 2014. View at Google Scholar
  9. B. Dell'Osso, A. Allen, and E. Hollander, “Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review,” Clinical Practice and Epidemiology in Mental Health, vol. 1, article 21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Angelucci, G. Martinotti, F. Gelfo et al., “Enhanced BDNF serum levels in patients with severe pathological gambling,” Addiction Biology, vol. 18, no. 4, pp. 749–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Hollander, C. M. Decaria, J. N. Finkell, T. Begaz, C. M. Wong, and C. Cartwright, “A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling,” Biological Psychiatry, vol. 47, no. 9, pp. 813–817, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. S. W. Kim, J. E. Grant, D. E. Adson, Y. Chul Shin, and R. Zaninelli, “A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling,” Journal of Clinical Psychiatry, vol. 63, no. 6, pp. 501–507, 2002. View at Google Scholar · View at Scopus
  13. J. E. Grant and M. N. Potenza, “Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation,” International Clinical Psychopharmacology, vol. 21, no. 4, pp. 203–209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Saiz-Ruiz, C. Blanco, A. Ibáñez et al., “Sertraline treatment of pathological gambling: a pilot study,” Journal of Clinical Psychiatry, vol. 66, no. 1, pp. 28–33, 2005. View at Google Scholar
  15. S. W. Kim and J. E. Grant, “An open naltrexone treatment study in pathological gambling disorder,” International Clinical Psychopharmacology, vol. 16, no. 5, pp. 285–289, 2001. View at Google Scholar · View at Scopus
  16. J. E. Grant, M. N. Potenza, E. Hollander et al., “Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling,” The American Journal of Psychiatry, vol. 163, no. 2, pp. 303–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Hollander, S. Pallanti, A. Allen, E. Sood, and N. B. Rossi, “Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?” The American Journal of Psychiatry, vol. 162, no. 1, pp. 137–145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Fong, A. Kalechstein, B. Bernhard, R. Rosenthal, and L. Rugle, “A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers,” Pharmacology Biochemistry and Behavior, vol. 89, no. 3, pp. 298–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. L. McElroy, E. B. Nelson, J. A. Welge, L. Kaehler, and P. E. Keck Jr., “Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 69, no. 3, pp. 433–440, 2008. View at Google Scholar · View at Scopus
  20. C. Blanco, E. Petkova, A. Ibáñez, and J. Sáiz-Ruiz, “A pilot placebo-controlled study of fluvoxamine for pathological gambling,” Annals of Clinical Psychiatry, vol. 14, pp. 9–15, 2002. View at Google Scholar
  21. P. N. Dannon, K. Lowengrub, Y. Gonopolski, E. Musin, and M. Kotler, “Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study,” Clinical Neuropharmacology, vol. 28, no. 1, pp. 6–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-K. Chung, I.-H. You, G.-H. Cho et al., “Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine,” Yonsei Medical Journal, vol. 50, no. 3, pp. 441–444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Grant, S. W. Kim, M. N. Potenza, C. Blanco, A. Ibáñez, L. Stevens et al., “Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial,” International Clinical Psychopharmacology, vol. 18, pp. 243–249, 2003. View at Google Scholar
  24. D. W. Black, M. Shaw, K. T. Forbush, and J. Allen, “An open-label trial of escitalopram in the treatment of pathological gambling,” Clinical Neuropharmacology, vol. 30, no. 4, pp. 206–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Zimmerman, R. B. Breen, and M. A. Posternak, “An open-label study of citalopram in the treatment of pathological gambling,” Journal of Clinical Psychiatry, vol. 63, no. 1, pp. 44–48, 2002. View at Google Scholar · View at Scopus
  26. D. W. Black, S. Arndt, W. H. Coryell et al., “Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study,” Journal of Clinical Psychopharmacology, vol. 27, no. 2, pp. 143–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. N. Dannon, K. Lowengrub, E. Musin, Y. Gonopolski, and M. Kotler, “Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study,” Journal of Clinical Psychopharmacology, vol. 25, no. 6, pp. 593–596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Grant, S. W. Kim, E. Hollander, and M. N. Potenza, “Predicting response to opiate antagonists and placebo in the treatment of pathological gambling,” Psychopharmacology, vol. 200, no. 4, pp. 521–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. E. Grant, W. K. Suck, and B. K. Hartman, “A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges,” Journal of Clinical Psychiatry, vol. 69, no. 5, pp. 783–789, 2008. View at Google Scholar · View at Scopus
  30. T. Toneatto, B. Brands, and P. Selby, “A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling,” The American Journal on Addictions, vol. 18, no. 3, pp. 219–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Rosenberg, L. K. Dinur, and P. N. Dannon, “Four-year follow-up study of pharmacological treatment in pathological gamblers,” Clinical Neuropharmacology, vol. 36, no. 2, pp. 42–45, 2013. View at Google Scholar
  32. R. I. Porchet, L. Boekhoudt, B. Studer et al., “Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers,” Frontiers in Behavioral Neuroscience, vol. 7, article 138, 2013. View at Google Scholar
  33. J. E. Grant, B. L. Odlaug, M. N. Potenza, E. Hollander, and S. W. Kim, “Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study,” British Journal of Psychiatry, vol. 197, pp. 330–331, 2010. View at Google Scholar
  34. M. Di Nicola, L. De Risio, M. Pettorruso et al., “Bipolar disorder and gambling disorder comorbidity: current evidence and treatment implications,” In press.
  35. S. Pallanti, L. Quercioli, E. Sood, and E. Hollander, “Lithium and valproate treatment of pathological gambling: a randomized single-blind study,” Journal of Clinical Psychiatry, vol. 63, no. 7, pp. 559–564, 2002. View at Google Scholar · View at Scopus
  36. E. Hollander, M. S. Buchsbaum, M. M. Haznedar et al., “FDG-PET study in pathological gamblers: 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism,” Neuropsychobiology, vol. 58, no. 1, pp. 37–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D. W. Black, M. C. Shaw, and J. Allen, “Extended release carbamazepine in the treatment of pathological gambling: an open-label study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 5, pp. 1191–1194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. H. A. Berlin, A. Braun, D. Simeon, L. M. Koran, M. N. Potenza, S. L. McElroy et al., “A double-blind, placebo-controlled trial of topiramate for pathological gambling,” World Journal of Biological Psychiatry, vol. 14, no. 2, pp. 121–128, 2013. View at Google Scholar
  39. M. Zack and C. X. Poulos, “Parallel roles for dopamine in pathological gambling and psychostimulant addiction,” Current Drug Abuse Reviews, vol. 2, no. 1, pp. 11–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. CA, K. M. Kampman, K. G. Lynch et al., “A double-blind, placebo-controlled trial of modafinil for cocaine dependence,” Journal of Substance Abuse Treatment, vol. 43, no. 3, pp. 303–312, 2012. View at Google Scholar
  41. H. R. Goez, O. Scott, N. Nevo, O. Bennett-Back, and N. Zelnik, “Using the test of variables of attention to determine the effectiveness of modafinil in children with attention-deficit hyperactivity disorder (ADHD): a prospective methylphenidate-controlled trial,” Journal of Child Neurology, vol. 27, no. 12, pp. 1547–1552, 2012. View at Google Scholar
  42. M. Zack and C. X. Poulos, “Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity,” Journal of Psychopharmacology, vol. 23, no. 6, pp. 660–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Smart, R. C. Desmond, C. X. Poulos, and M. Zack, “Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers,” Neuropharmacology, vol. 73, pp. 66–74, 2013. View at Google Scholar
  44. M. Zack and C. X. Poulos, “Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers,” Neuropsychopharmacology, vol. 29, no. 1, pp. 195–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Pettorruso, G. Conte, E. Righino et al., “Glutamatergic strategies in the treatment of pathological gambling: a pilot study,” European Psychiatry, vol. 28, Supplement 1, article 2876, p. 1, 2013. View at Google Scholar
  46. M. F. Olive, R. M. Cleva, P. W. Kalivas, and R. J. Malcolm, “Glutamatergic medications for the treatment of drug and behavioral addictions,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 801–810, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. E. Grant, S. W. Kim, and B. L. Odlaug, “N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study,” Biological Psychiatry, vol. 62, no. 6, pp. 652–657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. E. Grant, S. R. Chamberlain, B. L. Odlaug, M. N. Potenza, and S. W. Kim, “Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study,” Psychopharmacology, vol. 212, no. 4, pp. 603–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Thomas, L. Bonanni, F. Gambi, A. Di Iorio, and M. Onofrj, “Pathological gambling in parkinson disease is reduced by amantadine,” Annals of Neurology, vol. 68, no. 3, pp. 400–404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Pettorruso, G. Martinotti, M. Di Nicola et al., “Amantadine in the treatment of pathological gambling: a case report,” Front Psychiatry, vol. 3, article 102, 2012. View at Google Scholar
  51. D. W. Black, D. P. McNeilly, W. J. Burke, M. C. Shaw, and J. Allen, “An open-label trial of acamprosate in the treatment of pathological gambling,” Annals of Clinical Psychiatry, vol. 23, no. 4, pp. 250–256, 2011. View at Google Scholar · View at Scopus
  52. P. N. Dannon, O. Rosenberg, N. Schoenfeld, and M. Kotler, “Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study,” Front Psychiatry, vol. 2, article 33, 2011. View at Google Scholar
  53. S. Achab and Y. Khazaal, “Psychopharmacological treatment in pathological gambling: a critical review,” Current Pharmaceutical Design, vol. 17, no. 14, pp. 1389–1395, 2011. View at Publisher · View at Google Scholar · View at Scopus